The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes.

Jabbour, Elias; Garcia-Manero, Guillermo; Cornelison, A Megan; Cortes, Jorge E; Ravandi, Farhad; Daver, Naval; Kadia, Tapan; Teng, Angela; Kantarjian, Hagop

Jabbour, Elias; Garcia-Manero, Guillermo; Cornelison, A Megan; Cortes, Jorge E; Ravandi, Farhad; Daver, Naval; Kadia, Tapan; Teng, Angela; Kantarjian, Hagop.

Affiliation

Jabbour E; The MD Anderson Cancer Center , Houston, TX , USA.

Leuk Lymphoma ; 56(2): 390-4, 2015 Feb.

Article in En | MEDLINE | ID: mdl-24844364

Subject(s)

Azacitidine/analogs & derivatives; Leukemia, Myeloid/drug therapy; Myelodysplastic Syndromes/drug therapy; Acute Disease; Aged; Antimetabolites, Antineoplastic/therapeutic use; Azacitidine/therapeutic use; Decitabine; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid/pathology; Male; Middle Aged; Myelodysplastic Syndromes/pathology; Outcome Assessment, Health Care/methods; Outcome Assessment, Health Care/statistics & numerical data; Proportional Hazards Models; Retrospective Studies

Key words

Dacogen; decitabine; myelodysplastic syndromes; retrospective study

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Azacitidine / Myelodysplastic Syndromes / Leukemia, Myeloid Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Leuk Lymphoma Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2015 Document type: Article Affiliation country: United States Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google